Myriad Genetics Q3 2026 Results: Net Loss of $43.9M, Loss Widens
Myriad Genetics reported a revenue decline to $202.7 million for the third quarter of 2026, resulting in a net loss of $43.9 million. While the company significantly reduced its nine-month operating loss compared to the prior year—which was impacted by a $316.7 million impairment charge—it continues to face challenges with rising sales and marketing expenses.
- Key figure
- Net loss $43.9M